Wall Street analysts predict that BioScrip Inc (NASDAQ:BIOS) will announce $177.51 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings, with the lowest sales estimate coming in at $177.01 million and the highest estimate coming in at $178.00 million. BioScrip reported sales of $168.58 million during the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The company is expected to announce its next earnings results on Thursday, May 9th.
According to Zacks, analysts expect that BioScrip will report full-year sales of $754.46 million for the current financial year, with estimates ranging from $750.72 million to $761.65 million. For the next financial year, analysts anticipate that the firm will post sales of $800.52 million, with estimates ranging from $794.00 million to $807.03 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow BioScrip.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.11). The firm had revenue of $183.57 million during the quarter, compared to analyst estimates of $188.39 million. During the same period in the previous year, the company posted ($0.03) earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Venor Capital Management LP boosted its holdings in BioScrip by 0.3% in the third quarter. Venor Capital Management LP now owns 14,475,087 shares of the company’s stock valued at $44,873,000 after purchasing an additional 50,000 shares in the last quarter. BlackRock Inc. lifted its stake in BioScrip by 28.8% in the fourth quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock valued at $35,013,000 after buying an additional 2,191,490 shares during the last quarter. Vanguard Group Inc lifted its stake in BioScrip by 0.5% in the third quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after buying an additional 27,904 shares during the last quarter. Vanguard Group Inc. lifted its stake in BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after buying an additional 27,904 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in BioScrip by 7.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,617,021 shares of the company’s stock valued at $9,342,000 after buying an additional 180,389 shares during the last quarter. 82.51% of the stock is owned by hedge funds and other institutional investors.
Shares of BioScrip stock traded up $0.19 on Friday, reaching $2.00. 4,158,300 shares of the company were exchanged, compared to its average volume of 1,294,713. BioScrip has a 1-year low of $1.79 and a 1-year high of $4.14. The company has a market cap of $231.95 million, a PE ratio of -4.08 and a beta of 0.76.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Recommended Story: How to calculate the intrinsic value of a stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.